Mesoblast Limited (OTCMKTS:MEOBF – Get Free Report)’s stock price shot up 2.6% during trading on Wednesday . The company traded as high as $1.59 and last traded at $1.59. 500 shares changed hands during mid-day trading, a decline of 44% from the average session volume of 900 shares. The stock had previously closed at $1.55.
Mesoblast Trading Up 0.6%
The company has a 50 day simple moving average of $1.58 and a 200-day simple moving average of $1.58.
About Mesoblast
Mesoblast Limited (OTCMKTS:MEOBF) is a global leader in regenerative medicine focused on the development and commercialization of innovative allogeneic cell therapies. The company’s proprietary platform harnesses mesenchymal lineage adult stem cells to address a range of inflammatory and immunological conditions. Mesoblast’s pipeline includes multiple late-stage and marketed products that target serious diseases with high unmet medical needs.
The company’s lead product, remestemcel-L (Ryvicor/Ryoncil), is under development for the treatment of steroid-refractory acute graft versus host disease in pediatric patients and has received conditional approval for certain indications in Japan.
Featured Articles
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
